The US FDA has approved pembrolizumab as a single-agent first-line treatment for patients with stage III or metastatic non-small-cell lung cancer who have PD-L1 expression ≥1% and no EGFR or ALK mutations. The gene discussed is CD274; the disease is non-small cell lung carcinoma.